ZA200904079B - Human antibodies that bind CD22 and uses thereof - Google Patents
Human antibodies that bind CD22 and uses thereofInfo
- Publication number
- ZA200904079B ZA200904079B ZA200904079A ZA200904079A ZA200904079B ZA 200904079 B ZA200904079 B ZA 200904079B ZA 200904079 A ZA200904079 A ZA 200904079A ZA 200904079 A ZA200904079 A ZA 200904079A ZA 200904079 B ZA200904079 B ZA 200904079B
- Authority
- ZA
- South Africa
- Prior art keywords
- bind
- human antibodies
- antibodies
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86823106P | 2006-12-01 | 2006-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200904079B true ZA200904079B (en) | 2010-04-28 |
Family
ID=39493006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200904079A ZA200904079B (en) | 2006-12-01 | 2009-06-10 | Human antibodies that bind CD22 and uses thereof |
Country Status (17)
Country | Link |
---|---|
US (3) | US8481683B2 (xx) |
EP (1) | EP2097097B1 (xx) |
JP (2) | JP5398538B2 (xx) |
KR (2) | KR101552735B1 (xx) |
CN (2) | CN103172743B (xx) |
AR (1) | AR064109A1 (xx) |
BR (1) | BRPI0717902A2 (xx) |
CA (1) | CA2671457C (xx) |
CL (1) | CL2007003479A1 (xx) |
ES (1) | ES2678060T3 (xx) |
IL (1) | IL199036A (xx) |
MX (1) | MX2009005776A (xx) |
NZ (1) | NZ578064A (xx) |
SG (1) | SG177168A1 (xx) |
TW (1) | TWI447124B (xx) |
WO (1) | WO2008070569A2 (xx) |
ZA (1) | ZA200904079B (xx) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103172743B (zh) | 2006-12-01 | 2015-04-08 | 梅达雷克斯有限责任公司 | 结合cd22的人抗体及其用途 |
CN101815726B (zh) * | 2007-07-17 | 2013-04-03 | 米德列斯公司 | 针对磷脂酰肌醇蛋白聚糖-3的单克隆抗体 |
WO2009124109A1 (en) * | 2008-04-04 | 2009-10-08 | The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services | Human monoclonal antibodies specific for cd22 |
US9238878B2 (en) | 2009-02-17 | 2016-01-19 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
US9540438B2 (en) | 2011-01-14 | 2017-01-10 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof |
CN106928362B (zh) * | 2011-04-29 | 2021-10-26 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
AU2012298877B2 (en) | 2011-08-22 | 2018-01-04 | Emergent Biosolutions Canada Inc. | Clostridium difficile antibodies |
CN104159618B (zh) * | 2011-10-28 | 2018-06-01 | 弗雷达克斯有限责任公司 | 治疗剂及其用途 |
JP6113194B2 (ja) | 2012-02-13 | 2017-04-12 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | エンジイン化合物、その抱合体、ならびにその使用および方法 |
EP2818480B1 (en) * | 2012-02-24 | 2020-08-26 | Alteogen Inc. | Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same |
RU2014147452A (ru) * | 2012-04-26 | 2016-06-20 | Байоатла, Ллк | Анти-cd22 антитела |
EP3539563A1 (en) * | 2012-07-19 | 2019-09-18 | Redwood Bioscience, Inc. | Antibody specific for cd22 and methods of use thereof |
US9474803B2 (en) | 2012-11-27 | 2016-10-25 | Alteogen Inc. | Composition for stabilizing fusion protein in which protein and FC domain are fused |
SG11201506243XA (en) | 2013-02-14 | 2015-09-29 | Bristol Myers Squibb Co | Tubulysin compounds, methods of making and use |
SG10201707855YA (en) | 2013-03-13 | 2017-10-30 | Prothena Biosciences Ltd | Tau immunotherapy |
CN103214578B (zh) * | 2013-05-10 | 2014-05-28 | 北京东方百泰生物科技有限公司 | 一种新型的人源化抗cd22抗体 |
AU2014306592B2 (en) | 2013-08-14 | 2019-04-04 | Bristol-Myers Squibb Company | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
CN106133521A (zh) * | 2013-10-02 | 2016-11-16 | 苏瑞科技有限公司 | 用于治疗异质肿瘤的病患特异性的免疫疗法 |
US10100125B2 (en) | 2013-11-19 | 2018-10-16 | Diaprost Ab | Humanised anti kallikrein-2 antibody |
JPWO2015108203A1 (ja) * | 2014-01-15 | 2017-03-23 | 株式会社オーダーメードメディカルリサーチ | 抗slc6a6抗体を用いたがん治療用医薬組成物 |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
WO2015187519A1 (en) * | 2014-06-06 | 2015-12-10 | Merck Sharp & Dohme Corp. | Tslp assay |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
US9821059B2 (en) | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
RS60998B1 (sr) | 2014-11-21 | 2020-11-30 | Bristol Myers Squibb Co | Antitela koja sadrže modifikovane regione teškog lanca |
CA2973355A1 (en) | 2015-01-14 | 2016-07-21 | Bristol-Myers Squibb Company | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using |
IL292708B1 (en) | 2015-05-30 | 2024-04-01 | Molecular Templates Inc | Vaccine-free Shiga toxin A subunit scaffolds and cell-targeting molecules containing them |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
WO2017112624A1 (en) | 2015-12-21 | 2017-06-29 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
US11208632B2 (en) | 2016-04-26 | 2021-12-28 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
CN109415432B (zh) | 2016-05-02 | 2022-07-08 | 普罗塞纳生物科学有限公司 | Tau免疫疗法 |
PE20190261A1 (es) | 2016-05-02 | 2019-02-25 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
CA3022765A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
JP2019518013A (ja) | 2016-05-10 | 2019-06-27 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 安定性が向上したツブリシン類似体の抗体薬物結合体 |
US10287291B2 (en) | 2016-08-19 | 2019-05-14 | Bristol-Myers Squibb Company | Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use |
US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
BR112019022906A2 (pt) | 2017-05-02 | 2020-05-26 | Prothena Biosciences Limited | Anticorpos que reconhecem tau |
BR112019024419A2 (pt) | 2017-05-25 | 2020-07-14 | Bristol-Myers Squibb Company | anticorpos compreendendo regiões constantes pesadas modificadas |
KR20200021069A (ko) * | 2017-06-08 | 2020-02-27 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 조정 항체 |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
CN112888709A (zh) * | 2018-03-30 | 2021-06-01 | 优瑞科生物技术公司 | 标靶cd22的构建体和其用途 |
WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
MX2020012674A (es) | 2018-05-29 | 2021-02-09 | Bristol Myers Squibb Co | Porciones autoinmolantes modificadas para usarse en profarmacos y conjugados y metodos de uso y fabricacion. |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
KR20210096167A (ko) | 2018-11-28 | 2021-08-04 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 중쇄 불변 영역을 포함하는 항체 |
WO2020112588A1 (en) | 2018-11-30 | 2020-06-04 | Bristol-Myers Squibb Company | Antibody comprising a glutamine-containing light chain c-terminal extension, conjugates thereof, and methods and uses |
CN113544155A (zh) | 2018-12-12 | 2021-10-22 | 百时美施贵宝公司 | 经修饰用于转谷氨酰胺酶缀合的抗体、其缀合物以及方法和用途 |
CU20210073A7 (es) | 2019-03-03 | 2022-04-07 | Prothena Biosciences Ltd | Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs |
US20220177581A1 (en) * | 2019-03-11 | 2022-06-09 | Memorial Sloan Kettering Cancer Center | Cd22 antibodies and methods of using the same |
CN109970858B (zh) * | 2019-04-12 | 2023-05-09 | 深圳普瑞金生物药业股份有限公司 | Cd22单域抗体、核苷酸序列及试剂盒 |
WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
CA3177230A1 (en) * | 2020-04-02 | 2021-10-07 | Nanjing Iaso Biotherapeutics Co., Ltd. | Fully human anti-human cd22 chimeric antigen receptor and application thereof |
CN113527507A (zh) * | 2020-04-16 | 2021-10-22 | 上海赛比曼生物科技有限公司 | 靶向cd22的嵌合抗原受体及其制法和应用 |
KR20210143097A (ko) * | 2020-05-19 | 2021-11-26 | (주)이노베이션바이오 | Cd22에 특이적인 항체 및 이의 용도 |
KR20210143096A (ko) * | 2020-05-19 | 2021-11-26 | (주)이노베이션바이오 | Cd22에 특이적인 항체 및 이의 용도 |
JP2023527462A (ja) * | 2020-06-01 | 2023-06-28 | イノベイション バイオ カンパニー リミテッド | Cd22に特異的な抗体およびその使用 |
CN114075286A (zh) * | 2020-08-21 | 2022-02-22 | 张家港博泽利斯生物技术有限公司 | 一种抗人cxcr1蛋白单克隆抗体的制备方法 |
US20230416360A1 (en) * | 2020-12-03 | 2023-12-28 | Simcere Zaiming Pharmaceutical Co., Ltd. | Anti-cd22 nano antibody and use thereof |
KR20220122844A (ko) * | 2021-02-26 | 2022-09-05 | (주)이노베이션바이오 | Cd22에 특이적인 인간화 항체 및 이의 용도 |
CN114702585B (zh) * | 2021-11-26 | 2023-09-08 | 深圳宾德生物技术有限公司 | 一种抗cd22的单克隆抗体4f6及其制备方法和用途 |
WO2023216218A1 (zh) * | 2022-05-13 | 2023-11-16 | 上海吉倍生物技术有限公司 | Cd22特异性结合抗体及其制备方法和用途 |
Family Cites Families (190)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2484892A (en) * | 1946-05-22 | 1949-10-18 | Keston Reva Harris | Chewed gum receptacle |
US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4978757A (en) | 1984-02-21 | 1990-12-18 | The Upjohn Company | 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds |
US4912227A (en) | 1984-02-21 | 1990-03-27 | The Upjohn Company | 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5332837A (en) | 1986-12-19 | 1994-07-26 | The Upjohn Company | CC-1065 analogs |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5773435A (en) | 1987-08-04 | 1998-06-30 | Bristol-Myers Squibb Company | Prodrugs for β-lactamase and uses thereof |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5084468A (en) | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質dc113 |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Dc―88a誘導体 |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH05508394A (ja) | 1990-04-25 | 1993-11-25 | ファルマシア・アンド・アップジョン・カンパニー | 新規なcc―1065アナログ |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5864026A (en) | 1990-06-11 | 1999-01-26 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US5763566A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
US5789157A (en) | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US6261774B1 (en) | 1990-06-11 | 2001-07-17 | Gilead Sciences, Inc. | Truncation selex method |
US5712375A (en) | 1990-06-11 | 1998-01-27 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
GB9108652D0 (en) | 1991-04-23 | 1991-06-12 | Antisoma Ltd | Immunoreactive compounds |
JPH0597853A (ja) | 1991-10-07 | 1993-04-20 | Kyowa Hakko Kogyo Co Ltd | Dc−89誘導体の臭化水素酸塩 |
AU665221B2 (en) | 1991-12-02 | 1995-12-21 | Cambridge Antibody Technology Limited | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
GB9314960D0 (en) | 1992-07-23 | 1993-09-01 | Zeneca Ltd | Chemical compounds |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
DE69332643T2 (de) | 1992-09-16 | 2003-11-27 | Scripps Research Inst | Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
JP3919830B2 (ja) | 1992-11-28 | 2007-05-30 | 財団法人化学及血清療法研究所 | 抗ネコヘルペスウイルス−1組換え抗体および該抗体をコードする遺伝子断片 |
JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5484892A (en) | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
WO1995015969A1 (en) | 1993-12-09 | 1995-06-15 | Macquarie University | Glycozylhydrazines, preparation, immobilization and reactions of: glycoprotein analysis and o-glycan removal |
AU1866895A (en) | 1994-01-04 | 1995-08-01 | Scripps Research Institute, The | Human monoclonal antibodies to herpes simplex virus and methods therefor |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
CA2165819C (en) | 1994-04-22 | 2005-12-27 | Nobuyoshi Amishiro | Dc-89 derivatives |
JPH07309761A (ja) | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
IL114909A (en) | 1994-08-12 | 1999-10-28 | Immunomedics Inc | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
WO1996010405A1 (fr) | 1994-09-30 | 1996-04-11 | Kyowa Hakko Kogyo Co., Ltd. | Agent antitumoral |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6013443A (en) | 1995-05-03 | 2000-01-11 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
AU732961B2 (en) | 1995-05-03 | 2001-05-03 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
WO1997012862A1 (en) | 1995-10-03 | 1997-04-10 | The Scripps Research Institute | Cbi analogs of cc-1065 and the duocarmycins |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6183744B1 (en) | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
AU7274898A (en) | 1997-05-07 | 1998-11-27 | Bristol-Myers Squibb Company | Recombinant antibody-enzyme fusion proteins |
EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
EP0983248B1 (en) | 1997-05-22 | 2004-07-14 | The Scripps Research Institute | Analogs of duocarmycin and cc-1065 |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
GB9814383D0 (en) | 1998-07-02 | 1998-09-02 | Cambridge Antibody Tech | Improvements relating to antibodies |
AU5285899A (en) | 1998-07-21 | 2000-02-14 | Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh | Anti hepatitis c virus antibody and uses thereof |
ES2342637T3 (es) | 1998-12-11 | 2010-07-09 | Medarex, Inc. | Compuestos profarmacos y procedimiento para su preparacion. |
KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
DK2270147T4 (da) | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
US7829064B2 (en) | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
EP1543839B1 (en) * | 1999-06-09 | 2017-09-20 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target B-cells |
DE60042785D1 (de) | 1999-06-09 | 2009-10-01 | Immunomedics Inc | Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern |
US6387620B1 (en) | 1999-07-28 | 2002-05-14 | Gilead Sciences, Inc. | Transcription-free selex |
WO2001009187A2 (en) | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
WO2001095945A2 (en) | 2000-06-14 | 2001-12-20 | Medarex, Inc. | Prodrug compounds cleavable by thimet oligopeptidase |
JP2004501875A (ja) | 2000-06-14 | 2004-01-22 | メダレックス,インコーポレイティド | トリペプチドプロドラッグ化合物 |
JP2004510702A (ja) | 2000-06-14 | 2004-04-08 | メダレックス,インコーポレイティド | イソロイシンを有するプロドラッグ化合物 |
EP2052742A1 (en) | 2000-06-20 | 2009-04-29 | Biogen Idec Inc. | Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination |
CA2421447C (en) | 2000-09-08 | 2012-05-08 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
WO2002030984A1 (en) * | 2000-10-13 | 2002-04-18 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
US20060223114A1 (en) | 2001-04-26 | 2006-10-05 | Avidia Research Institute | Protein scaffolds and uses thereof |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
US20030082630A1 (en) | 2001-04-26 | 2003-05-01 | Maxygen, Inc. | Combinatorial libraries of monomer domains |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
EP2009027B1 (en) * | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
ATE398172T1 (de) | 2001-05-11 | 2008-07-15 | Kirin Pharma Kk | Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper |
JP2004532038A (ja) | 2001-05-17 | 2004-10-21 | ディヴァーサ コーポレイション | 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法 |
AU2002303929B9 (en) | 2001-05-31 | 2007-01-25 | E. R. Squibb & Sons, L.L.C. | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
US6897034B2 (en) | 2001-06-11 | 2005-05-24 | Medarex, Inc. | CD10-activated prodrug compounds |
JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
EP1539233B1 (en) * | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
KR20040054669A (ko) * | 2001-08-03 | 2004-06-25 | 글리카트 바이오테크놀로지 아게 | 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체 |
EP1423110A4 (en) | 2001-09-07 | 2005-04-27 | Scripps Research Inst | CBI ANALOGUE OF CC-1065 AND DUOCARMYCINES |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
ATE468348T1 (de) * | 2001-09-26 | 2010-06-15 | Government Of The Us Secretary | Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen |
CN100423777C (zh) | 2001-10-25 | 2008-10-08 | 杰南技术公司 | 糖蛋白组合物 |
US20060191026A1 (en) | 2005-02-18 | 2006-08-24 | Origen Therapeutics, Inc. | Tissue specific expression of antibodies in chickens |
JP2005526044A (ja) * | 2002-02-21 | 2005-09-02 | デューク ユニバーシティ | 抗cd22抗体を使用した治療方法 |
DE60333732D1 (de) | 2002-03-01 | 2010-09-23 | Immunomedics Inc | Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
CA2481657A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
ES2916174T3 (es) * | 2002-05-02 | 2022-06-28 | Wyeth Holdings Llc | Conjugados de transportador derivado de caliqueamicina |
US7456260B2 (en) | 2002-06-17 | 2008-11-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Humanized antibody |
JP2006512895A (ja) | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
AU2003286004A1 (en) | 2002-11-08 | 2004-06-07 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
EP1578801A2 (en) | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
EP2357237A1 (en) | 2003-05-14 | 2011-08-17 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
SI1639011T1 (sl) | 2003-06-30 | 2009-04-30 | Domantis Ltd | Pegilirana protitelesa z enojno domeno (dAb) |
JP4751326B2 (ja) | 2003-09-04 | 2011-08-17 | メダレックス インコーポレイテッド | 発現ベクター |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
WO2005052006A2 (en) | 2003-11-25 | 2005-06-09 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Mutated anti-cd22 antibodies and immunoconjugates |
US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
AU2005307789A1 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
EP1844073A1 (en) | 2005-01-31 | 2007-10-17 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
MX2007014148A (es) * | 2005-05-19 | 2008-01-11 | Amgen Inc | Composiciones y metodos para incrementar la estabilidad de anticuerpos. |
CA2622441A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
CA2627981A1 (en) | 2005-11-07 | 2007-05-18 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
CA2627190A1 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
KR20080090406A (ko) | 2005-11-28 | 2008-10-08 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
CA2637254A1 (en) | 2006-01-17 | 2007-07-26 | Biolex Therapeutics, Inc. | Compositions and methods for humanization and optimization of n-glycans in plants |
AU2007223903B2 (en) * | 2006-03-06 | 2013-09-05 | Medimmune, Llc | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
KR101328756B1 (ko) | 2006-05-30 | 2013-11-18 | 제넨테크, 인크. | 항체 및 면역접합체 및 이들의 용도 |
CN103172743B (zh) | 2006-12-01 | 2015-04-08 | 梅达雷克斯有限责任公司 | 结合cd22的人抗体及其用途 |
-
2007
- 2007-11-30 CN CN201310052225.7A patent/CN103172743B/zh not_active Expired - Fee Related
- 2007-11-30 CN CN2007800504656A patent/CN101626782B/zh not_active Expired - Fee Related
- 2007-11-30 CA CA2671457A patent/CA2671457C/en not_active Expired - Fee Related
- 2007-11-30 SG SG2011088838A patent/SG177168A1/en unknown
- 2007-11-30 KR KR1020097013205A patent/KR101552735B1/ko not_active IP Right Cessation
- 2007-11-30 KR KR1020157014396A patent/KR20150067395A/ko not_active Application Discontinuation
- 2007-11-30 US US12/517,183 patent/US8481683B2/en not_active Expired - Fee Related
- 2007-11-30 MX MX2009005776A patent/MX2009005776A/es active IP Right Grant
- 2007-11-30 TW TW096145829A patent/TWI447124B/zh not_active IP Right Cessation
- 2007-11-30 ES ES07854887.2T patent/ES2678060T3/es active Active
- 2007-11-30 NZ NZ578064A patent/NZ578064A/en not_active IP Right Cessation
- 2007-11-30 BR BRPI0717902-2A2A patent/BRPI0717902A2/pt not_active Application Discontinuation
- 2007-11-30 EP EP07854887.2A patent/EP2097097B1/en active Active
- 2007-11-30 WO PCT/US2007/086152 patent/WO2008070569A2/en active Application Filing
- 2007-11-30 JP JP2009539520A patent/JP5398538B2/ja not_active Expired - Fee Related
- 2007-12-03 CL CL2007003479A patent/CL2007003479A1/es unknown
- 2007-12-03 AR ARP070105393A patent/AR064109A1/es not_active Application Discontinuation
-
2009
- 2009-05-31 IL IL199036A patent/IL199036A/en active IP Right Grant
- 2009-06-10 ZA ZA200904079A patent/ZA200904079B/xx unknown
-
2013
- 2013-02-20 US US13/772,063 patent/US9499632B2/en not_active Expired - Fee Related
- 2013-09-02 JP JP2013180953A patent/JP5846695B2/ja not_active Expired - Fee Related
-
2016
- 2016-11-10 US US15/348,551 patent/US20170058031A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL199036A0 (en) | Human antibodies that bind cd22 and uses thereof | |
EP2101817A4 (en) | CD19 BINDING HUMAN ANTIBODIES AND THEIR USE | |
HK1208228A1 (en) | Antibodies and immunoconjugates and uses therefor | |
ZA200902256B (en) | Human antibodies that bind cxcr4 and uses thereof | |
IL198592A0 (en) | Tes7 and antibodies that bind thereto | |
HK1182721A1 (zh) | 抗體和免疫偶聯物及其用途 | |
EP2097534A4 (en) | HUMAN ANTIBODIES BINDING TO CD70 AND USES THEREOF | |
ZA200807755B (en) | Anti-tat226 antibodies and immunoconjugates | |
ZA200809776B (en) | Antibodies and immunoconjugates and uses therefor | |
IL195658A0 (en) | Anti-nkg2a antibodies and uses thereof | |
IL200610A0 (en) | Human monoclonal anti-ip-10 antibodies and uses thereof | |
SI2061814T1 (sl) | Protitelesa in imunokonjugati in njihove uporabe | |
ZA200904657B (en) | Human antibodies that bind CD70 and uses thereof | |
ZA200904424B (en) | Human antibodies that bind CD19 and uses thereof |